Compare iShares MSCI China ETF (MCHI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs ResMed Inc. — how do they compare? iShares MSCI China ETF trades at $52.04 (market cap $5.94B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 5.4× iShares MSCI China ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and ResMed Inc. for 51 Days on average.
| MCHI | RMD | |
|---|---|---|
Market Cap | $5.94B | $31.89B |
Volume | 1,575,471 | 618,314 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $277.88 |
52-Week Low | $50.48 | $182.82 |
Typical Hold Time | 63 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $51.64, down 1.11% with a bearish technical outlook. The ETF faces pressure from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights mixed signals with strong corporate profit growth but concerns about export controls and trade tensions. Technical indicators show strong bearish momentum with moving averages signaling sell pressure while oscillators remain neutral.
The outlook remains cautious given China's macroeconomic headwinds and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations compared to US indices, but risks include potential export restrictions, protectionism threats, and ongoing economic rebalancing challenges that could pressure Chinese equities.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
